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ABSTRACT
Objective: Side effects due to chemotherapy were frequently reported and some of them require immediate treatment. Cervical cancer, breast cancer, 
and ovarian cancer are types of cancer that are often found in Dr. Moewardi Surakarta Hospital and 45% of the three types of cancer used the 
chemotherapy regimen of carboplatin-paclitaxel. Carboplatin-paclitaxel was chosen because it is a regimen that has fewer side effects.
Methods: This study aims to identify the type of adverse drug reactions (ADRs) neurotoxicity, percentage, and severity, as well as to determine the 
risk factors for the occurrence of ADRs such as age, gender, type of cancer, number of cycles, length of stay, and types of comorbidities in cancer 
patients using carboplatin-paclitaxel therapy regimen in RSUD Dr. Moewardi Surakarta for the period September to December 2019. This study was 
an observational study with a cross-sectional design through prospective data searches. The inclusion criteria in this study were adult cancer patients 
on carboplatin-paclitaxel therapy who were willing to be research subjects.
Results: The incidences of ADRs in patients using the carboplatin-paclitaxel therapy regimen in this study were sensory peripheral neuropathy (77.69%); 
motor peripheral neuropathy (3.31%); joint pain (53.72%); and muscle weakness (37.19%) The instrument to measure the severity in this study used 
common terminology criteria for adverse events with the results of ADRs with grade 1 (35.08%), grade 2 (61.02), grade 3 (2.88%), and at grades 4 
and 5 (0%). Risk factors for gender, age, length of stay, type of cancer, number of cycles, and comorbidities did not affect the incidence of neurotoxicity 
in cancer patients with the carboplatin-paclitaxel therapy regimen.
Keywords: Adverse drug reactions, Neuropathy, Sensory, Motor, Joint, Muscle, Carboplatin, Paclitaxel, Common terminology criteria for adverse 
events, Number of cycles.
INTRODUCTION
Cancer is a disease characterized by continuously abnormal growth 
cells because cancer cells are lack or fail to respond to homeostatic 
mechanisms in controlling cell division [1]. Research at 185 countries 
in 2018, a total of 18.1 million patients were diagnosed with cancer and 
9.6 million died [2]. Cancer is a disease that causes high mortality, so 
the development of cancer drugs is the priority. Standard antineoplastic 
therapies including cytotoxic chemotherapy have the risk of adverse 
events. New antineoplastics are increasing, so the diversity of adverse 
drug reactions (ADRs) is increasing. Factors that influence ADRs 
are antineoplastic types, frequency, ethnic diversity, and disease 
severity [3].
Carboplatin-paclitaxel is a chemotherapy regimen used for lung cancer, 
ovarian cancer, breast cancer, cervical cancer, and cancer of the digestive 
tract [4]. ADRs carboplatin-paclitaxel regimen in patients with ovarian 
cancer with percentage >10% is edema, headache, insomnia, asthenia, 
fatigue, pain, back pain, alopecia, hypokalemia, dyspepsia, anorexia, 
constipation, diarrhea, nausea, vomiting, mucositis, stomatitis, anemia, 
granulocytopenia, leukopenia, neutropenia, thrombocytopenia, fever, 
infection, arthralgia, myalgia, motor neuropathy, sensory neuropathy, 
paresthesia, peripheral neuropathy, and dyspnea [5].
Adverse reactions carboplatin with incidence >10% are pain, 
hyponatremia, hypomagnesemia, hypocalcemia, hypokalemia, nausea, 
vomiting, leukopenia, thrombocytopenia, anemia, neutropenia, 
increased SGOT and SGPT values, weakness, decreased creatinine 
clearance, and increased BUN values. Adverse reactions to paclitaxel 
whose incidence >10% are edema, hypertension, fever, pain, 
dysesthesia, rash, pruritus, erythema, gastrointestinal disturbances, 
proteinuria, cough, and rhinitis [6]. Patient who uses paclitaxel cisplatin 
and paclitaxel carboplatin is decrease in hemoglobin, thrombocyte, as 
well as leukocyte values [7].
The carboplatin-paclitaxel regimen can be used for several types of 
cancer. Research of ADRs neurotoxicity carboplatin-paclitaxel does not 
find, so it is necessary to do research on this in patients who use the 
regimen of carboplatin-paclitaxel. This study can provide information 
about the type of neurotoxicity, percentage, and severity of patients 
who use carboplatin-paclitaxel at Dr. Moewardi Hospital Surakarta, 
with the hope of anticipating side effects during the treatment period 
so can increase quality of life patient’s.
METHODS
This study used an observational study with a cross-sectional design 
through prospective data searches leading to a cohort through medical 
records of cancer patients who used the carboplatin-paclitaxel regimen 
at Dr. Moewardi Hospital Surakarta. Patients identified ADRs using 
common terminology criteria for adverse events (CTCAE) and Naranjo’s 
instrument. The independent variable is age, gender, type of cancer, 
number of cycles, length of stay, and comorbidities. This research was 
conducted for 4 months, starting from September to December 2019 at 
RSUD Dr. Moewardi Surakarta. Samples were determined by consecutive 
sampling method with inclusion and exclusion criteria as follows:
Inclusion criteria
a. Adult cancer patient
b. Patient receiving Carboplatin-Paclitaxel regiment
c. Complete data about independent variables (gender, age, type of 
cancer, number of cycles, length of stay, and comorbidities)
d. Patients are willing to be research respondents, prove by signing 
informed consent.
© 2021 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons.org/
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Exclusion criteria
a. Patients with HIV, tuberculosis, liver disorders, kidney disorders, 
mental disorders, and gastrointestinal disorders
b. Lost follow-up.
This analysis was used to analyze the relationship between independent 
variables (age, gender, type of cancer, number of cycles, length of 
hospitalization, and comorbidities) and dependent variables (sensory 
peripheral neuropathy, motor peripheral neuropathy, joint pain, and 
muscle weakness). Analysis data will use contingency coefficients if 
type data nominal versus nominal and will use Eta analysis when type 
data nominal versus numerical.
RESULTS AND DISCUSSION
The number of patients who used carboplatin-paclitaxel therapy 
regimen in October-December is 121 patients and 100% female. All 
patients is female because in this hospital the carboplatin-paclitaxel 
regimen was used for chemotherapy in cervical cancer, ovarian cancer, 
and breast cancer. Women have a higher incidence of cancer, possibly 
because of differences in hormones, namely estrogen and progestin, 
which are found more in women. In addition, menopause is also a 
risk factor for cancer [8]. In this study, patients aged 46–65 years had 
a higher percentage. This is similar to research that there is a direct 
correlation between increasing age and levels of ADRs [9]. The complete 
data of characteristic sample are shown in Table 1.
Based on characteristic data patients who use carboplatin-paclitaxel 
are 31.4% ovarian cancer, 36.4% cervical cancer, and 32.2% breast 
cancer. Carboplatin-paclitaxel is the primary therapeutic regimen used 
in adjuvant therapy of all stages of ovarian cancer [5]. Carboplatin-
paclitaxel is the first line of therapy for advanced breast cancer [10]. 
Therapy for cervical cancer varies according to the patient’s condition, 
carboplatin-paclitaxel is used in the treatment of relapsed and 
metastatic cervical cancer [11]. One of the advantages of combination 
carboplatin-paclitaxel is less toxic than cisplatin and paclitaxel, but it 
is necessary to pay attention at platelet value, incidence of alopecia, 
and symptoms of neuropathy [12]. Another study said that the use of 
the carboplatin-paclitaxel combination had a higher success rate than 
the cisplatin-paclitaxel combination [13]. A total of 140 ADRs were 
reported from platinum analogs following treatment of different types 
of cancer in hospital. Most of the ADRs that happen to patient were 
observed in the age group of 40–60 years. Vomiting (27 ADRs) was 
commonly reported reaction. Among platinum analogs, cisplatin leads 
to 82 ADRs (58.57%) followed by carboplatin with 53 ADRs (37.86%) 
and least with oxaliplatin 5 ADRs (3.57%) [14].
Carboplatin-paclitaxel therapy regimen in patients with ovarian cancer, 
cervical cancer, and breast cancer was used every 21 days for 6 cycles. 
In this study, patients who take second-cycle chemotherapy have the 
highest percentage. Patients with a higher number of cycles have a 
higher risk of experiencing ADRs [15].
In Table 2, sensory peripheral neuropathy (77.79%) became the most 
common ADRs in the area of  muscle and joint disorders, followed by joint 
pain (53.72%), muscle weakness (37.19%), and peripheral neuropathy 
motoric (3.31%). Routine use of platinum agents such as oxaliplatin, 
cisplatin, and equal portions in combination with carboplatin-paclitaxel 
can cause long-term damage to peripheral sensors. Peripheral sensor 
ADRs occur in 30–40% of patients taking these agents. Paclitaxel which 
is a taxane class of drugs also triggers neuropathy [16]. Single paclitaxel 
therapy resulted in 9.52% experiencing muscle weakness [17]. 
Peripheral neuropathy was experienced in 46.6% of patients after 
chemotherapy with a carboplatin-paclitaxel regimen [18].
This study analyzed the relationship of risk factors to the incidence 
of peripheral neuropathy sensory, peripheral neuropathy motoric, 
arthralgia, and muscle weakness. The risk factors tested were gender, 
age, type of cancer, number of cycles, length of stay, and comorbidities. 
Bivariate analysis used contingency coefficients for risk factors cancer 
type and comorbidities. Bivariate analysis using Eta for risk factors length 
of stay, age, and the number of cycles. The results of all bivariate analyze 
is p-value>0.05* so it can be concluded that the risk factors gender, age, 
type of cancer, number of cycles, length of stay, and comorbidities have 
no effect on neurotoxicity due to carboplatin-paclitaxel. This is different 
from the study in Nepal which stated that older patient has a higher 
incidence of ADRs. The higher incidence of ADRs may be related to organ 
function which can result in low metabolic capacity and decreased 
drug excretion which can accumulate drugs in the body thereby 
increasing the risk of ADRs [19]. Patients without comorbidities, having 
hypertension, diabetes mellitus, hypertension+diabetes mellitus, 
Table 2: Incident neurotoxicity and severity carboplatin‑paclitaxel regiment
ADRs Incident (n=121) (%) Grade 1 CTCAE (%) Grade 2 CTCAE (%) Grade 3 CTCAE (%)
Peripheral neuropathy sensory 94 (77.69) 25 (12.01) 66 (31.7) 3 (1.44)
Peripheral neuropathy motoric 4 (3.31) 3 (1.44) 1 (0.48) 0
Arthalgia 65 (53.72) 22 (10.57) 42 (20.19) 1 (0.48)
Muscles weakness 45 (37.19) 23 (11.06) 18 (8.65) 2 (0.96)
ADR: Adverse drug reactions, CTCAE: Common terminology criteria for adverse events
Table 1: Characteristics of patients using the 
paclitaxel‑carboplatin regimen in cancer patients at  
Dr. Moewardi Hospital Surakarta
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and hypertension+diabetes mellitus+asthma had no association 
with neurotoxicity. In contrast to Zhang’s et al. research which states 
that comorbidities can increase the incidence of ADRs due to cardiac 
insufficiency, lung, kidney, and liver damage can cause changes in 
pharmacokinetics or pharmacodynamics [20]. A study of 157 patients 
undergoing chemotherapy showed that smoking, consuming alcohol, 
having an age of >70 years, and being overweight were at high risk for 
increasing the incidence of ADRs [21].
CONCLUSION
The incidences of ADRs in patients using carboplatin-paclitaxel therapy 
regimen in this study were peripheral neuropathy sensory (77.69%); 
peripheral neuropathy motoric (3.31%); arthralgia (53.72%); and 
muscle weakness (37.19%) The instrument to measure the severity in 
this study used CTCAE with the results of ADRs with grade 1 (35.08%), 
grade 2 (61.02), grade 3 (2.88%), and at grades 4 and 5 (0%). Risk 
factors gender, age, length of stay, type of cancer, number of cycles, and 
comorbidities has not affected the incidence of neurotoxicity in patients 
with carboplatin-paclitaxel therapy. This study expected can anticipate 
side effects during the treatment period to increase the effectiveness of 
therapy and the quality of life of patients.
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